EFFECTIVENESS OF TENOFOVIR-LAMIVUDIN-EFAVIRENZ (TLE) COMBINATION COMPARED TO TENOFOVIR-LAMIVUDIN- DOLUTEGRAVIR (TLD) IN HIV PATIENTS AT UPTD PUSKESMAS IBRAHIM ADJIE BANDUNG

• Main Author: Basuki
• Format: Theses
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/85312
• Institution: Institut Teknologi Bandung

Antiretroviral (ARV) is a medication administered to treat HIV infection and reduce the risk of HIV transmission, inhibit the exacerbation of opportunistic infections, improve the quality of life of HIV patients, and decrease the number of viruses in the blood until undetected. The aim of this study was to compare the effectiveness of the Tenofovir-Lamividin-Efavirenz (TLE) Fixed-Dose Combination (KDT) with Tenofobir- Lamivudin-Dolutegravir (TLD) in HIV patients to identify factors that influence virus suppressiveness. This research is an analytical observational study with a cross-sectional approach and a comparative study design. (comparative study). The data was collected retrospectively using secondary data from medical records, Kemenkes HIV AIDS Information System (SIHA), laboratory tests (viral load) and drug use pill count reports. The research population was HIV patients who were given TLE and TLD therapy at the Technical Services Executive Unit (UPTD) Puskesmas Ibrahim Adjie Kota Bandung in February 2022 until February 2023. The total population meeting the inclusion criteria was 197 people consisting of 90 TLE users and 107 TLD users. Statistical tests showed no significant difference in viral load between TLE and TLD therapeutic users (p-value=0.74). But the percentage of undetected virus load was higher in TLE users (92.22%) compared to TLD (90.65%). The level of viral supressivity between TLD and TLE patients also did not show any significant difference (p=0.46), although the proportion of TLD users who achieved supresivity was higher (99.1%) compared with TLE (97.8%) and had a relatively lower rate of compliance with TLD (67.29%) than TLE (84.44%) and a shorter duration (mean=34.58 months) of the TLE therapy than the average (Mean=81.1month). The test of each variable for viral supressivity showed that the factors that significantly influence viral Supresivity (pvalue <0,01) are a history of comorbid disease. (hipertensi). Although there are no statistically significant differences between TLE and TLD, TLD shows better virus supressiveness than TLE.